Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 8 December 2009
Vol. 2, Issue 100, p. ra80
[DOI: 10.1126/scisignal.2000643]

RESEARCH ARTICLES

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

Andrea Bertotti1, Mike F. Burbridge2*, Stefania Gastaldi1*, Francesco Galimi1*, Davide Torti1*, Enzo Medico3, Silvia Giordano1, Simona Corso1, Gaëlle Rolland-Valognes4, Brian P. Lockhart4, John A. Hickman2, Paolo M. Comoglio1{dagger}, and Livio Trusolino1{dagger}

1 Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
2 Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.
3 Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.
4 Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.

* These authors contributed equally to this work.

Abstract: Tumor onset and progression require the accumulation of many genetic and epigenetic lesions. In some cases, however, cancer cells rely on only one of these lesions to maintain their malignant properties, and this dependence results in tumor regression upon oncogene inactivation ("oncogene addiction"). Determining which nodes of the many networks operative in the transformed phenotype specifically mediate this response to oncogene neutralization is crucial to identifying the vulnerabilities of cancer. Using the Met receptor as the major model system, we combined multiplex phosphoproteomics, genome-wide expression profiling, and functional assays in various cancer cells addicted to oncogenic receptor tyrosine kinases. We found that Met blockade affected a limited subset of Met downstream signals: Little or no effect was observed for several pathways downstream of Met; instead, only a restricted and pathway-specific signature of transducers and transcriptional effectors downstream of Ras or phosphoinositide 3-kinase (PI3K) was inactivated. An analogous signature was also generated by inhibition of epidermal growth factor receptor in a different cellular context, suggesting a stereotyped response that likely is independent of receptor type or tissue origin. Biologically, Met inhibition led to cell-cycle arrest. Inhibition of Ras-dependent signals and PI3K-dependent signals also resulted in cell-cycle arrest, whereas cells in which Met was inhibited proliferated when Ras or PI3K signaling was active. These findings uncover "dominant" and "recessive" nodes among the numerous oncogenic networks regulated by receptor tyrosine kinases and active in cancer, with the Ras and PI3K pathways as determinants of therapeutic response.

{dagger} To whom correspondence should be addressed. E-mail: livio.trusolino{at}ircc.it (L.T.) and paolo.comoglio{at}ircc.it (P.M.C.)

Citation: A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino, Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Sci. Signal. 2, ra80 (2009).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab.
M. F. Burbridge, C. J. Bossard, C. Saunier, I. Fejes, A. Bruno, S. Leonce, G. Ferry, G. Da Violante, F. Bouzom, V. Cattan, et al. (2013)
Mol. Cancer Ther. 12, 1749-1762
   Abstract »    Full Text »    PDF »
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET.
C. Basilico, S. Pennacchietti, E. Vigna, C. Chiriaco, S. Arena, A. Bardelli, D. Valdembri, G. Serini, and P. Michieli (2013)
Clin. Cancer Res. 19, 2381-2392
   Abstract »    Full Text »    PDF »
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas.
G. Migliardi, F. Sassi, D. Torti, F. Galimi, E. R. Zanella, M. Buscarino, D. Ribero, A. Muratore, P. Massucco, A. Pisacane, et al. (2012)
Clin. Cancer Res. 18, 2515-2525
   Abstract »    Full Text »    PDF »
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils.
D. Torti and L. Trusolino (2011)
EMBO Mol Med. 3, 623-636
   Abstract »    Full Text »    PDF »
A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer.
A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, C. Isella, D. Cora, F. Di Nicolantonio, M. Buscarino, C. Petti, et al. (2011)
Cancer Discovery 1, 508-523
   Abstract »    Full Text »    PDF »
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors.
V. Cepero, J. R. Sierra, S. Corso, E. Ghiso, L. Casorzo, T. Perera, P. M. Comoglio, and S. Giordano (2010)
Cancer Res. 70, 7580-7590
   Abstract »    Full Text »    PDF »
Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors.
A. Bertotti, C. Bracco, F. Girolami, D. Torti, S. Gastaldi, F. Galimi, E. Medico, P. Elvin, P. M. Comoglio, and L. Trusolino (2010)
Clin. Cancer Res. 16, 3933-3943
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882